Table 4. Summary of miRs with altered expression, their potential targets and pathways entered in this study.
| microRNA (Ref.) | Expression | Potential target | Pathway |
|---|---|---|---|
| miR-26b (11) | Low | USP9X, TAK1, TAB3, CDK8, PTGS2, SLC7A11 | Cell growth, apoptosis, EMT and NF-κB signaling pathways |
| miR-20a (12) | High | E2F2, E2F3 | Cell proliferation and modulate translation |
| miR-10a (12) | High | E2F2, E2F3 | Cell invasion and metastasis |
| miR-335 (13) | Low | MERTK, Rb1, SP1, BRCA1, RUNX2, PTPRN2, TRIM29 | EMT, PTEN/AKT/mTOR signaling pathways |
| miR-145 (14) | Low | p53 | Cell invasion and transcription |
| miR-107 (15) | High | CCR5 | Cell proliferation and invasion |
| miR-130a (15) | High | Tap63 | Cell migration, invasion and metastasis |
| miR-215 (16) | Low | BRAF, KRAS, TP53, RUNX1 | Cell migration, invasion and malignant progression |
| miR-205 (17) | Low | CYR61, CTGF | Cell proliferation and migration |
| miR-363-3p (18) | Low | CREB1, NOTCH1 | Cell proliferation, migration and apoptosis |
| miR-31 (19) | High | ARID1A | cell proliferation, apoptosis, migration and invasion |
| miR-126 (20) | Low | EGFL7, ADAM9b, VEGF-A, CRK | VEGF/PI3K-AKT signaling pathways |
| miR-497 (21) | Low | IGF-1R | Cell growth, proliferation, migration and invasion |
| miR-224 (22) | High | RKIP | Cell metastasis, growth and proliferation |
| miR-125b (23) | Low | BAK1, ErbB2 | Cell motility, invasion, glucose metabolism and chemosensitivity |
| miR-100 (23) | Low | RPSP3, PLK1, mTOR | Cell growth and migration |
| miR-143 (23) | Low | DNMT3A, KRAS, BCL-2 | Cell proliferation, apoptosis and metastasis |
| miR-145 (23) | Low | BNIP3, IRS, C-MYC, YES, STAT1, MMP-11, ADAM-17 | Cell proliferation, apoptosis and metastasis |
| miR-199a-5p (23) | Low | DDR1, SWI, SNF, PAK4 | Cell invasion and migration |
EMT: epithelial-to-mesenchymal transition; NF-κB: Nuclear factor-κB; VEGF: vascular endothelial growth factor; PI3K: phosphoinositol 3-kinase; AKT: serine/threonine kinase; PTEN: phosphatase and tensin homologue; mTOR: mammalian target of rapamycin.